Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Treatment Approaches for Secondary AML

Cancer; ePub 2017 Aug 15; Boddu, et al

Publish date:: September 6, 2017

Patients with secondary acute myeloid leukemia (s-AML) who received less intense treatment experienced lower earlier mortality and better overall survival than those on intensive regimens, according to a study involving 931 individuals.

Participants were between 60 and 75 years of age and newly diagnosed with s-AML. Investigators looked at outcomes by the type of treatment received. Among the results:

Patients receiving hypomethylating agents or low-dose cytarabine combinations experienced average overall survival of nearly 7 months, vs 5.4 months for those who received intensive chemotherapy (IC).
4% of the IC group received transplantation, vs 10% of the those on lower intensity regimens.
Patients receiving CPX-351 and those treated with lower intensity approaches experienced similar median survival.
Lower overall survival rates were seen in patients who were 1) >70 years of age, 2) had an adverse karyotype, and 3) had a prior antecedent hematologic disorder.

Citation:

Boddu P, Kantarjian H, Ravandi F, et al. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. [Published online ahead of print August 15, 2017]. Cancer. doi:10.1002/cncr.30704.

This Week's Must Reads

Phase II Trial of DNA Vaccine Encoding PAP in Patients with PCa ,

Utilization of Surgery for Post-prostatectomy Incontinence,

Claims Analysis of Advanced PCa Treatment Costs and Resource Use,

Testosterone Therapy Doesn't Increase Prostate Cancer Risk,

Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced PCa,

Must Reads in AML

Immune system changes play a role in AML relapse, Christopher MJ et al. N Engl J Med. 2018 Oct 31. doi: 10.1056/NEJMoa1808777.

Venetoclax plus HMA studied in AML, DiNardo C et al. Blood. 2018 Oct 25. doi: 10.1182/blood-2018-08-868752.

T cell infusion effective in PML, Muftuoglu M et al. N Engl J Med. 2018 Oct 11;379:1443-51

Higher AML, MDS risk linked to autotransplants, Radivoyevitch T et al. Leuk Res. 2018 Jul 19. pii: S0145-2126(18)30160-7

Tibsovo for AML with IDH1 mutation, FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation, FDA press release